Halozyme Therapeutics (HALO) Tops Q4 EPS by 3c; Guides FY15 Revs
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Halozyme Therapeutics (HALO) PT Raised to $26 at BMO Capital
March 3, 2015 7:23 AM ESTBMO Capital analyst Jim Birchenough reiterated an Outperform rating and boosted his price target on Halozyme Therapeutics (NASDAQ: HALO) to $26.00 (from $24.00) following Q4 results.
Birchenough commented, "We are reiterating our Outperform rating on the shares of HALO following review of 4Q14 progress.... More
Halozyme Therapeutics (HALO) Raised to $19 at Piper Jaffray
March 3, 2015 7:17 AM ESTPiper Jaffray analyst Charles Duncan reiterated an Overweight rating and boosted his price target on Halozyme Therapeutics (NASDAQ: HALO) to $19.00 (from $17.00) following Q4 results.. The firm said proprietary program visibility should increase in 2015.
Duncan commented, "On Monday AMC, Halozyme reported 4Q/FY14 results, reiterating 2015... More
